Oriola (OKDBV) Q4 2025 earnings summary

Executive summary

• Net sales increased by 14% year-over-year to EUR 1,906 million, with adjusted EBITDA rising to EUR 35.1 million, driven by strong growth in both Distribution and Wholesale segments and improved customer satisfaction.

• Strategic focus included customer partnerships, expanded services, operational efficiency, and sustainability achievements, with a 40% reduction in Scope 1 and 2 emissions since 2023.

• Completed integration of Kronans Apotek joint venture, launching commercial initiatives and achieving a 2.9% sales growth in local currency.

• Major investments included ERP/WMS upgrades and approval for a new automated distribution centre in Finland valued at EUR 110-120 million.

Financial highlights

• Invoicing grew 13% to EUR 4,201 million and net sales rose 14% to EUR 1,906 million, with sales margin up 4.4% to EUR 166.8 million.

• Adjusted EBITDA reached EUR 35.1 million, up from EUR 33.4 million, while reported EBITDA was lower due to ERP and logistics costs.

• Net profit was negative at EUR -27.2 million, impacted by ERP costs, impairments, and joint venture losses.

• Free cash flow improved to EUR 58.4 million from EUR 43.4 million last year.

• Cash and cash equivalents rose to EUR 152.2 million, with net interest-bearing debt at EUR -82.1 million.

Outlook and guidance

• Adjusted EBITDA is expected to increase in 2026, supported by efficiency initiatives, market growth, and ongoing strategy execution.

• Capital Markets Day scheduled for May 12, 2026, to update on long-term plans, financial targets, and capital allocation.

• Pharmaceutical distribution market anticipated to grow, but geopolitical and supply chain uncertainties persist.